View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 17, 2022

Ivy Brain Tumor Center begins trial of AstraZeneca’s therapy for glioma

The open-label, single-centre trial will analyse AZD1390 in up to 21 subjects with a recurrent glioma who need re-radiation.

The Ivy Brain Tumor Center at the Barrow Neurological Institute in the US has launched a Phase 0/Ib clinical trial of AstraZeneca’s AZD1390 in recurrent grade IV glioma patients. 

AZD1390 is an inhibitor of Ataxia telangiectasia mutant (ATM) kinase. 

The open-label, single-centre trial will enrol up to 21 subjects with a recurrent glioma who need re-radiation.  

The Ben and Catherine Ivy Foundation and the Barrow Neurological Foundation’s individual donors are funding the trial.

Validating the blood-brain barrier penetration of AZD1390 and analysing if it can boost the efficacy of radiation therapy are the goals of the trial.

Subjects with tumours showing favourable pharmacokinetics (PK) response in the Phase 0 segment of the trial will advance to the expansion Phase Ib portion.

AZD1390 will be administered along with the standard of care fractionated radiotherapy in the Phase Ib portion.

Based on findings from the active Phase I multicentre trial of AZD1390 currently underway, the maximum safe dose-level of the drug will be chosen for the Phase 0 trial.

This Phase I trial is analysing the safety, tolerability and systemic pharmacokinetics of ascending doses of AZD1390 along with radiation therapy for brain cancer patients. 

Ivy Brain Tumor Center chief operating officer and deputy director Shwetal Mehta said: “AZD1390 is a novel agent by AstraZeneca, specifically designed to cross the blood-brain barrier. 

“The drug targets ATM kinase, an essential factor that promotes the repair of DNA double-strand breaks caused by radiation treatment.” 

The US Food and Drug Administration introduced the Phase 0 trial approach in 2004 to expedite the assessment and approval process of drugs and enhance new therapies to enter the clinic. 

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU